Global study to evaluate uproleselan in 380 patients with Relapsed/Refractory AML (Image: GlycoMimetics)
The biotech sector is a fast growing market opportunity for investors, especially those with a taste for high risk and long-term views. Biotechnology is the technological application of modifying
GlycoMimetics (GLYC) is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which
Company chart and information is provided by TradingView based on 15-minute-delayed data.
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
| Website: | www.glycomimetics.com |
| Email: | info@glycomimetics.com. |
| Main Phone: | +1 240 243-1201 |
| Address: | 9708 Medical Center Drive |
| Address 2: | Suite 1700 |
| State: | MD |
| City / Town: | Rockville |
| Country: | US |
| Postal Code: | 20850 |
| Exchange: | NSD |
| CEO: | Rachel K. King |
| Employees: | 54 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Global study to evaluate uproleselan in 380 patients with Relapsed/Refractory AML (Image: GlycoMimetics)
The biotech sector is a fast growing market opportunity for investors, especially those with a taste for high risk and long-term views. Biotechnology is the technological application of modifying
GlycoMimetics (GLYC) is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which
Each week, we tap the insight of Sam Stovall, Chief Equity Strategist for S&P Capital IQ, for his perspective on the current market.EQ: October is coming to a close, which means that investors
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
